Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.01M Buy
34,563
+9,105
+36% +$495K ﹤0.01% 2618
2026
Q1
$1.48M Buy
25,458
+10,696
+72% +$581K ﹤0.01% 2558
2025
Q4
$681K Buy
+14,762
New +$660K ﹤0.01% 2761
2025
Q3
Sell
-6,381
Closed -$207K 3553
2025
Q2
$207K Sell
6,381
-191
-3% -$6.26K ﹤0.01% 3032
2025
Q1
$248K Sell
6,572
-17,944
-73% -$1.43M ﹤0.01% 2775
2024
Q4
$2.01M Buy
24,516
+13,403
+121% +$1.33M ﹤0.01% 1536
2024
Q3
$1.27M Buy
11,113
+253
+2% +$22.8K ﹤0.01% 1737
2024
Q2
$820K Buy
10,860
+328
+3% +$22.3K ﹤0.01% 1841
2024
Q1
$719K Sell
10,532
-1,568
-13% -$109K ﹤0.01% 1819
2023
Q4
$760K Sell
12,100
-400
-3% -$20.8K ﹤0.01% 1709
2023
Q3
$637K Sell
12,500
-1,870
-13% -$92.3K ﹤0.01% 1765
2023
Q2
$718K Buy
14,370
+1,627
+13% +$77.1K ﹤0.01% 1685
2023
Q1
$478K Buy
12,743
+1,306
+11% +$55.4K ﹤0.01% 1796
2022
Q4
$548K Buy
11,437
+2,111
+23% +$82.8K ﹤0.01% 1781
2022
Q3
$224K Buy
+9,326
New +$236K ﹤0.01% 2020

Other funds holding PCVX

Cliff Asness's PCVX Position: Q2 2026 in Review

Cliff Asness increased its Vaxcyte (PCVX) stake by 36% in Q2 2026, buying an estimated $495K and bringing the position to 34,563 shares worth $2.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2618.

Cliff Asness first reported a position in PCVX in Q3 2022 and has held it in 15 quarters since. 330 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Cliff Asness held 34,563 shares of Vaxcyte worth $2.01M as of Q2 2026.
  • Cliff Asness bought 9,105 Vaxcyte shares in Q2 2026, an estimated $495K.
  • Vaxcyte made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2618 holding.
  • Cliff Asness first reported a position in Vaxcyte in Q3 2022 and has held it in 15 quarters since.
  • 330 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.